Literature DB >> 19532081

Manifestations and management of lymphogranuloma venereum.

John A White1.   

Abstract

PURPOSE OF REVIEW: This review was prompted by a sustained outbreak of lymphogranuloma venereum that has been observed among men who have sex with men (MSM) worldwide since 2004. Recent developments in the epidemiology, diagnosis and management of the infection are summarized. RECENT
FINDINGS: Between the early 1980s and 2003, lymphogranuloma venereum was rarely seen in the developed world. In 2003, a cluster of cases was seen in the Netherlands occurring mostly in HIV-positive MSM with high levels of sexual risk. With the assistance of novel molecular diagnostic techniques, more than a thousand cases of Chlamydia trachomatis L2 serovar disease have now been reported in MSM worldwide. Almost all have presented with rectal infection, usually manifesting as severe proctitis, with ulcer adenopathy syndrome seldom seen. Oral doxycycline remains the recommended treatment and has proven effective in the recent outbreak. Conflicting data exist regarding the prevalence of asymptomatic infection, and our understanding of the exact modes of transmission remains incomplete.
SUMMARY: Lymphogranuloma venereum appears to have reestablished endemicity among MSM populations in many industrialized nations. In the relative absence of recent publications from its traditional endemic regions it can be assumed that these populations remain afflicted by the infection as well.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19532081     DOI: 10.1097/QCO.0b013e328320a8ae

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  22 in total

1.  [Diagnosis and treatment of Chlamydia trachomatis infections].

Authors:  T Meyer
Journal:  Hautarzt       Date:  2012-01       Impact factor: 0.751

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  [Sexually Transmitted Infections in the Tropics].

Authors:  C Bendick
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 4.  Approach to lymphogranuloma venereum.

Authors:  Patrick O'Byrne; Paul MacPherson; Stephane DeLaplante; Gila Metz; Andree Bourgault
Journal:  Can Fam Physician       Date:  2016-07       Impact factor: 3.275

Review 5.  [Diagnosis and therapy of genitoanal ulcers of infectious etiology].

Authors:  B Malisiewicz; H Schöfer
Journal:  Hautarzt       Date:  2015-01       Impact factor: 0.751

6.  Minimum spread of the new Swedish variant of Chlamydia trachomatis and distribution of C. trachomatis ompA genotypes in three geographically distant areas of Spain, 2011-2012.

Authors:  L Piñeiro; S Bernal; A Bordes; J C Palomares; R Gilarranz; M A von Wichmann; G Cilla
Journal:  Infection       Date:  2014-07-24       Impact factor: 3.553

7.  Genotyping Chlamydia trachomatis strains among men who have sex with men from a Northern Spain region: a cohort study.

Authors:  P Mejuto; J A Boga; M Junquera; A Torreblanca; P S Leiva
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

Review 8.  Infectious proctitis: when to suspect it is not inflammatory bowel disease.

Authors:  Frank Hoentjen; David T Rubin
Journal:  Dig Dis Sci       Date:  2011-10-13       Impact factor: 3.487

9.  Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages.

Authors:  Naraporn Somboonna; Raymond Wan; David M Ojcius; Matthew A Pettengill; Sandeep J Joseph; Alexander Chang; Ray Hsu; Timothy D Read; Deborah Dean
Journal:  MBio       Date:  2011-05-03       Impact factor: 7.867

10.  Multi locus sequence typing of Chlamydia reveals an association between Chlamydia psittaci genotypes and host species.

Authors:  Yvonne Pannekoek; Veerle Dickx; Delphine S A Beeckman; Keith A Jolley; Wendy C Keijzers; Evangelia Vretou; Martin C J Maiden; Daisy Vanrompay; Arie van der Ende
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.